Abstract 295P
Background
Volumetric arc therapy (VMAT) with Simultaneous Integrated Boost (SIB) allows radiotherapy dose escalation to the region of involved nodes also reducing toxicity in node-positive patients of cervical cancer. Aim of this study was to evaluate the early outcome and acute toxicity with chemo-radiation usingVMAT with SIB in patients with locally advanced cervical cancer.
Methods
Thirty-three newly diagnosed cases of carcinoma cervix having Positron emission tomography (PET) positive pelvic/para-aortic nodes were included after obtaining a written informed consent. The complete clinical assessment and staging was performed. All patients were treated by VMAT with SIB technique to the dose of 50.4Gy to the primary site with draining nodes and 58.8Gy to PET positive nodes in 28 fractions followed by HDR brachytherapy boost of 7Gy in three fractions. Concurrent cisplatin at the dose of 40mg/m2 was administered on weekly basis during External beam radiotherapy. Acute toxicity was assessed according to the RTOG Acute Radiation Morbidity scoring criteria. Post treatment response was assessed by clinical examination and PET-CT /CECT scans at 3months.
Results
Median age was 55 years(range 35-70). The mean tumor size was 5.7cm (range 3.5-9) with 90% patients having disease more than 4cm. Median Standardized uptake value maximum in PET at primary tumor and LN was 17.3 and 8.7 respectively. Pelvic node only was seen in 23(69.6%) patients while Para-aortic node was involved in ten. Bladder and rectum invasion was seen in four and two patients respectively.Twenty-six (79%) patients received four or more cycles of concurrent Cisplatin. The median overall treatment time was 62 days. Response assessment at 3months showed complete response in 27 patients (82%), partial response in four while progressive disease in two patients. Maximum grade of toxicity at 3 months in skin, gastrointestinal, and hematological was grade I whereas one patient had grade III genitourinary toxicity. At last follow up, 30 patients were alive while three patients died; two deaths due to disease.
Conclusions
VMAT with SIB to involved nodes to higher doses results in effective early loco-regional control with acceptable acute toxicities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Mishra.
Funding
Institute of Eminence, Banaras Hindu University, Varanasi.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract